Signature Development and Validation Protocol for an Epigenetic Assay in Diagnosing Breast Cancer

This clinical testing protocol outlines the validation process for an epigenetic assay targeting host peripheral blood cell and the associated host DNA methylation signatures designed to diagnose breast cancer. The overall protocol process will involve three distinct stages representing three patient cohorts with up to 150 subjects per cohort across 3 populations of patients. Cohort one will act as signature development phase; cohort two will act as signature finalization phase; and cohort three will act as a validation cohort phase. Each cohort with include the following patient populations with up to 50 patients per population: 1. Breast cancer, NO chemotherapy. Includes patients treated with surgical resection and/or radiation therapy and/or endocrine therapy 2. Breast cancer who have received chemotherapy. Includes all stages including remission 3. At risk group (patients at increased risk for breast cancer followed in a high risk breast program)